Navigation Links
Xenome Names Ian T. Nisbet, PhD as Chief Executive Officer
Date:2/5/2008

BRISBANE, Australia, Feb. 5 /PRNewswire/ -- Xenome Limited today announced the appointment of Ian Nisbet, PhD as the Company's Chief Executive Officer. Dr. Nisbet will also join Xenome's Board as Managing Director.

Dr. Nisbet has previously worked in senior management and executive roles in a number of biotechnology companies, including ChemGenex Pharmaceuticals Ltd, Meditech Research Ltd, Millennium Pharmaceuticals Inc, and CSL Ltd. He is a founder and partner in the biotechnology consultancy company Afandin Pty Ltd. He also serves on the board of the biotechnology companies Verva Pharmaceuticals Ltd, Ambri Ltd and Velacor Pty Ltd.

Xenome Chairman Ian Sandford stated, "We are delighted to have recruited Ian Nisbet to join Xenome. The Company has just executed a major discovery partnership with Amylin Pharmaceuticals and we will soon initiate a Xen2174 phase II study in post-operative pain. With the leadership of such an experienced biotechnology executive as Ian we look forward to the coming year with tremendous excitement and confidence."

"Ian's skills and experience make him the ideal person to lead Xenome in its next stage of development. Ian has worked in a variety of project management, business development, product development and executive management roles. During his time at Millennium he was project leader for the US approval and launch of VELCADE(R) and was part of the team that managed the merger of Millennium and COR Therapeutics in 2001. During his period as CEO of Meditech, Ian led the negotiations with Alchemia that resulted in the first merger of two publicly-traded Australian biotechnology companies."

Dr. Nisbet will assume the CEO position immediately and transition from his existing consultancy commitments over the next several months.

Further information:

Ian Nisbet, Chief Executive Officer

Xenome Ltd.

Tel: +61 431 709 121

E-mail: ian.nisbet@xenome.com

Website: http://www.xenome.com

About Xenome - Biopharmaceutical Discovery

Xenome is a biotechnology company that is focused on the discovery and development of peptide-based therapeutics. The Company's lead product, Xen2174, is a novel conopeptide analogue for the treatment of pain. An international phase I/II clinical trial in patients with cancer pain is in its final stages of completion and a phase II study in post-operative pain is due to commence in 2008. Xen2174 is the first product to emerge from the Company's discovery platform, which is based on a proprietary library of venom peptides. Late in 2007 Xenome and Amylin Pharmaceuticals entered into a partnership to screen Xenome's library for new drug candidates against metabolic disease targets. Both Xen2174 and the Amylin partnership leverage off Xenome's unique expertise in peptide chemistry and its ability to translate the evolutionary advantages inherent in venom peptides into libraries of highly bioactive molecules.

Xenome Ltd. ABN 60 081 612 384

120 Meirs Rd. Indooroopilly, Brisbane, QLD 4068, Australia

PO Box 6295, St Lucia, Brisbane, QLD 4067, Australia

ph: +61 7 3720 8055

fax: +61 7 3720 8388

web: http://www.xenome.com

email: discovery@xenome.com


'/>"/>
SOURCE Xenome Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
2. Profectus BioSciences Inc. Names Shawn Patrick OBrien CEO
3. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
4. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
5. Premier Research Names Patrick Melvin as Senior Director, Clinical Trial Management
6. DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences
7. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
8. Quintiles Names Kelly McKee Executive Director of Operations for Public Health and Government Services Unit
9. SRA Names Timothy J. Atkin Senior Vice President of Global Health Business; Appoints Mike Toner Global Health Unit Chief Financial Officer
10. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2016)... (PRWEB) , ... May 22, 2016 , ... Doctors in ... in combating the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article ... in the University of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more ...
(Date:5/20/2016)... ... , ... The recent recall by Costco and Trader Joes of 47 million ... 12, 2016(1), demonstrates the need for faster and more cost effective bio-threat detection to ... , PathSensor’s latest solution uses a biosensor technology called CANARY®. ...
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and ... Siddiqui as Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more ... discovery studies for preclinical and clinical safety programs. “We’ve seen significant demand for, ...
(Date:5/18/2016)... COLUMBIA, Md. (PRWEB) , ... May 18, 2016 ... ... new Shimadzu Pharmaceutical Sciences Summer Camp at The University of Toledo. This two-day ... school students an opportunity to explore the field of pharmaceutical sciences in preparation ...
Breaking Biology Technology:
(Date:5/9/2016)... DUBAI , UAE, May 9, 2016 ... choice when it comes to expanding freedom for high ... Even in today,s globally connected world, there ... online conferencing system could ever duplicate sealing your deal ... are obtaining second passports by taking advantage of citizenship ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
Breaking Biology News(10 mins):